RYTM Stock Summary and Trading Ideas (Rhythm Pharmaceuticals | NASDAQ:RYTM)

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Rhythm Pharmaceuticals trades on the NASDAQ stock market under the symbol RYTM.

As of December 19, 2025, RYTM stock price climbed to $112.14 with 1,327,395 million shares trading.

RYTM has a beta of 1.29, meaning it tends to be more sensitive to market movements. RYTM has a correlation of 0.19 to the broad based SPY ETF.

RYTM has a market cap of $7.48 billion. This is considered a Mid Cap stock.

Last quarter Rhythm Pharmaceuticals reported $51 million in Revenue and -$.82 earnings per share. This beat revenue expectation by $813,242 and missed earnings estimates by -$.10.

In the last 3 years, RYTM traded as high as $122.20 and as low as $15.50.

The top ETF exchange traded funds that RYTM belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.

RYTM has outperformed the market in the last year with a price return of +102.1% while the SPY ETF gained +18.1%. RYTM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.7% and +7.2%, respectively, while the SPY returned +2.8% and -0.5%, respectively.

RYTM support price is $107.91 and resistance is $115.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RYTM shares will trade within this expected range on the day.